Eli Lilly & Co.'s SEC filings document the regulatory record for its pharmaceutical business, listed common stock and NYSE-traded notes. Forms 8-K report operating results and financial condition, annual meeting vote outcomes, director and officer matters, underwriting agreements and other material events tied to the company's capital structure and governance.
Proxy filings provide formal disclosure on board elections, executive compensation, shareholder voting matters and pay-versus-performance information. The company's exchange-listed securities include no-par common stock under LLY and multiple series of notes with maturities extending across its debt capital structure.
Eli Lilly and Company is offering $9,000,000,000 of unsecured notes in multiple series due 2028 through 2066, including floating-rate notes tied to Compounded SOFR and several fixed-rate notes with coupons from 4.150% to 5.700%. The offering proceeds are expected to be used for general corporate purposes, including repayment of commercial paper and potentially to fund upfront cash consideration and fees for the pending acquisitions of Centessa Pharmaceuticals plc and Kelonia Therapeutics, Inc. The Centessa-related series (the Centessa Mandatorily Redeemable Notes) include a special mandatory redemption provision that requires redemption at 101% of principal plus accrued interest if the Centessa Acquisition is not consummated by specified outside dates or if Lilly elects not to pursue the acquisition.
Eli Lilly and Company reported results of its 2026 annual shareholders meeting. Shareholders voted 847,254,010 common shares, about 90% of the 944,818,881 shares outstanding and entitled to vote as of February 25, 2026.
Four director nominees were elected to three-year terms, shareholders approved on an advisory basis the compensation of named executive officers, and ratified Ernst & Young LLP as independent auditor for 2026. Proposals to amend the Articles of Incorporation to eliminate the classified board structure and supermajority voting provisions received majority support but did not meet the required 80% of outstanding shares. Shareholder proposals for an independent board chair and for an annual lobbying report were not approved.
Lilly Endowment Inc, a former 10% shareholder of ELI LILLY & Co, sold a total of 15,828 shares of common stock in open-market transactions. The sales occurred at weighted average prices of about $995.23 and $996.18 per share, with execution prices ranging from $995.00 to $996.46. After these transactions, Lilly Endowment continues to hold about 91,883,358 shares of Eli Lilly common stock.
Eli Lilly and Company is offering multiple series of unsecured, unsubordinated debt securities (floating rate and fixed rate notes) pursuant to a preliminary prospectus supplement. The company intends to use net proceeds for general corporate purposes, including repayment of commercial paper and potentially to fund all or a portion of the upfront cash consideration for its pending Centessa and Kelonia acquisitions. Certain series (the “Centessa Mandatorily Redeemable Notes”) are subject to a special mandatory redemption if the Centessa Acquisition is not consummated by five business days after the later of March 31, 2027 (or any agreed Outside Date); those notes would be redeemable at 101% of principal plus accrued interest. The floating rate notes reference Compounded SOFR (with related Benchmark Transition provisions). Notes will be issued in minimum denominations of $2,000 and delivered in book-entry form through DTC, Clearstream and Euroclear.
Eli Lilly & Co reported a Schedule 13G ownership disclosure showing Vanguard Capital Management beneficially owns 61,295,605 shares of Common Stock, representing 6.48% of the class. The filing states Vanguard has sole dispositive power over 61,295,605 shares and sole voting power over 7,933,831 shares. The disclosure names affiliated Vanguard entities and notes holdings include securities held for Vanguard funds and managed accounts. The signature date is 05/01/2026.
Eli Lilly posted very strong Q1 2026 results, with revenue of $19.8 billion, up 56% from a year earlier, and diluted EPS of $8.26 versus $3.06. Net income rose to $7.4 billion, a 168% increase.
Growth was driven by incretin medicines. Mounjaro generated $8.7 billion in revenue and Zepbound $4.2 billion, and together with other cardiometabolic drugs they made up 65% of total revenue. International sales nearly doubled, helped by Mounjaro launches, though prices fell in some markets such as China.
Research and development spending increased 28% to $3.5 billion as Lilly advanced an extensive late-stage pipeline, while acquired in-process R&D charges dropped sharply. Operating cash flow reached $5.3 billion, funding heavy capital investment, the $1.1 billion Ventyx acquisition, $2.3 billion of share repurchases, and $1.5 billion in dividends. Management highlights rising pricing and reimbursement pressure, including U.S. drug pricing reforms and new agreements that lower certain prices, as key risks alongside the company’s growing reliance on incretin therapies.
Eli Lilly (LLY) reported very strong first-quarter 2026 results and raised its full-year outlook. Q1 2026 revenue rose 56% to $19.8 billion, driven by a 65% increase in volume, partially offset by lower realized prices, especially for Mounjaro and Zepbound. Reported EPS increased 170% to $8.26, while non-GAAP EPS rose 156% to $8.55, helped by lower acquired IPR&D charges versus last year.
Key obesity and diabetes medicines continued to power growth: Mounjaro revenue jumped 125% to $8.7 billion, and Zepbound revenue grew 80% to $4.2 billion. Lilly also reported rapid growth across newer immunology, oncology, and neuroscience products. U.S. revenue grew 43% to $12.1 billion, while revenue outside the U.S. rose 81% to $7.7 billion.
The company raised 2026 guidance, now expecting full-year revenue of $82–$85 billion and non-GAAP EPS of $35.50–$37.00. Gross margin stayed above 80% on both a reported and non-GAAP basis, even as the company increased spending on research, development, and launches. Lilly highlighted the U.S. FDA approval and launch of Foundayo, its once-daily oral GLP-1 pill for weight loss, plus multiple positive Phase 3 results and several announced acquisitions to expand its pipeline.
Eli Lilly & Co director Gabrielle Sulzberger received a compensation-related stock grant rather than buying shares on the market. On this award, she acquired 5.39 shares of common stock at $919.90 per share, bringing her direct holdings to 2,981.599 shares.
According to the disclosure, she elected to defer this grant into stock units under the Lilly Directors' Deferral Plan. These units will be settled in Eli Lilly common stock after she separates from board service, turning current cash compensation into future share-based value.